USIR : unité pivot des détresses respiratoires : une année de pandémie à SARS-CoV-2

por Foulquier, S., Noel-Savina, E., Pontier, S., Mazieres, J., Didier, A.
Publicado 2022

The prognostic impact of immune-related adverse events during anti-PD1 treatment in melanoma and non–small-cell lung cancer: a real-life retrospective study

por Dupont, R., Bérard, E., Puisset, F., Comont, T., Delord, J.-P., Guimbaud, R., Meyer, N., Mazieres, J., Alric, L.
Publicado 2019

DNA replication stress response involving PLK1, CDC6, POLQ, RAD51 and CLASPIN upregulation prognoses the outcome of early/mid-stage non-small cell lung cancer patients

por Allera-Moreau, C, Rouquette, I, Lepage, B, Oumouhou, N, Walschaerts, M, Leconte, E, Schilling, V, Gordien, K, Brouchet, L, Delisle, M B, Mazieres, J, Hoffmann, J S, Pasero, P, Cazaux, C
Publicado 2012

Severe SARS-CoV-2 pneumonia: Clinical, functional and imaging outcomes at 4 months

por Noel-Savina, E., Viatgé, T., Faviez, G., Lepage, B., Mhanna, L.t, Pontier, S., Dupuis, M., Collot, S., Thomas, P., Idoate Lacasia, J., Crognier, L., Bouharaoua, S., Silva Sifontes, S., Mazieres, J., Prévot, G., Didier, A.
Publicado 2021

Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-c...

por Wolf, J., Helland, Å., Oh, I.-J., Migliorino, M.R., Dziadziuszko, R., Wrona, A., de Castro, J., Mazieres, J., Griesinger, F., Chlistalla, M., Cardona, A., Ruf, T., Trunzer, K., Smoljanovic, V., Novello, S.
Publicado 2022

Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study)

por Raynaud, C., Greillier, L., Mazieres, J., Monnet, I., Mastroianni, B., Robinet, G., Fraboulet, G., Dixmier, A., Berard, H., Lamy, R., Letreut, J., Lena, H., Oliviero, G., Botta, S., Vergnenegre, A., Borget, I., Chouaid, C.
Publicado 2015

Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%

por Pons-Tostivint, E., Hulo, P., Guardiolle, V., Bodot, L., Rabeau, A., Porte, M., Hiret, S., Demontrond, P., Curcio, H., Boudoussier, A., Veillon, R., Mayenga, M., Dumenil, C., Chatellier, T., Gourraud, P. A., Mazieres, J., Bennouna, J.
Publicado 2023

Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%

por Pons-Tostivint, E., Hulo, P., Guardiolle, V., Bodot, L., Rabeau, A., Porte, M., Hiret, S., Demontrond, P., Curcio, H., Boudoussier, A., Veillon, R., Mayenga, M., Dumenil, C., Chatellier, T., Gourraud, P. A., Mazieres, J., Bennouna, J.
Publicado 2023

Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study

por Novello, S, Mazières, J, Oh, I -J, de Castro, J, Migliorino, M R, Helland, Å, Dziadziuszko, R, Griesinger, F, Kotb, A, Zeaiter, A, Cardona, A, Balas, B, Johannsdottir, H K, Das-Gupta, A, Wolf, J
Publicado 2018

Proposals for managing patients with thoracic malignancies during COVID-19 pandemic

por Girard, N., Greillier, L., Zalcman, G., Cadranel, J., Moro-Sibilot, D., Mazières, J., Audigier-Valette, C., Bennouna, J., Besse, B., Cortot, A., Couraud, S., Duruisseaux, M., Giroux-Leprieur, E., Toffart, A.-C., Westeel, V., Wislez, M.
Publicado 2020

Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform

por Morfouace, M., Novello, S., Stevovic, A., Dooms, C., Janžič, U., Berghmans, T., Dziadziuszko, R., Gorlia, T., Felip, E., Paz-Ares, L., Mazieres, J., O’Brien, M., Bironzo, P., Vansteenkiste, J., Lacroix, L., Dingemans, A. C., Golfinopoulos, V., Besse, B.
Publicado 2022

IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer

por Molinier, O., Besse, B., Barlesi, F., Audigier-Valette, C., Friard, S., Monnet, I., Jeannin, G., Mazières, J., Cadranel, J., Hureaux, J., Hilgers, W., Quoix, E., Coudert, B., Moro-Sibilot, D., Fauchon, E., Westeel, V., Brun, P., Langlais, A., Morin, F., Souquet, P.J., Girard, N.
Publicado 2021

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

por Mazieres, J., Drilon, A., Lusque, A., Mhanna, L., Cortot, A.B., Mezquita, L., Thai, A.A., Mascaux, C., Couraud, S., Veillon, R., Van den Heuvel, M., Neal, J., Peled, N., Früh, M., Ng, T.L., Gounant, V., Popat, S., Diebold, J., Sabari, J., Zhu, V.W., Rothschild, S.I., Bironzo, P., Martinez-Marti, A., Curioni-Fontecedro, A., Rosell, R., Lattuca-Truc, M., Wiesweg, M., Besse, B., Solomon, B., Barlesi, F., Schouten, R.D., Wakelee, H., Camidge, D.R., Zalcman, G., Novello, S., Ou, S.I., Milia, J., Gautschi, O.
Publicado 2019